The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.
 
Jared Cohen
No Relationships to Disclose
 
Jessica C. Ley
No Relationships to Disclose
 
Jingxia Liu
No Relationships to Disclose
 
Emma Haselhorst
No Relationships to Disclose
 
Peter John Oppelt
Speakers' Bureau - Bristol Myers Squibb; Eisai; Merck
Research Funding - Enzychem Lifesciences (Inst); HiFiBiO Therapeutics (Inst); Merck (Inst)
 
Douglas Adkins
Consulting or Advisory Role - Boehringer Ingelheim; Calliditas Therapeutics; CUE Biopharma; Eisai Europe; Exelixis; Genmab/Seattle Genetics; Gilead Sciences; Immunitas; Jazz Pharmaceuticals; Kura Oncology; Merck; Seagen; TargImmune Therapeutics; Vaccinex
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Genmab (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst)